Login
Cardiovascular Systems NASDAQ: CSII
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
| Name | Cardiovascular Systems |
| Ticker | CSII |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Price | 35.39 |
| 52W Low/High | 27.86 / 54.18 |
| Market cap | 1.4 B |
| 1Y Total Return |
-22.32%
Below Average |
| 1Y Volatility |
52.53%
Less Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Cardiovascular Systems, Inc., a medical technology company, develops, manufactures, and markets devices to treat vascular diseases
Details
| Ticker | CSII |
| Name | Cardiovascular Systems |
| ISIN | US1416191062 |
| CUSIP | 141619106 |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Specialized Medical Devices |
| Country | USA |
| Currency | U.S. Dollar |
Share as of 11/27/20
| Close Price | 35.39 |
| 52W Low/High | 27.86 / 54.18 |
| Market cap | 1.4 B |
| 1Y Total Return |
-22.32%
Below Average |
| 1Y Volatility |
52.53%
Less Risk |
| Beta | 2.45 |
| PE (trailing) | - |
| 12M Dividends | - |
| Last Dividend Date | - |
| Dividend Yield | - |
Fin. Strength
| Net Profit Margin | -10.1% |
| Cash from Op. / Cur. Liabilities | -0.20 |
| Diluted Earnings / Share | -0.67 |
| ROE | - |
| ROIC | -14.7% |
| Price / Revenue | 5.9 |
| Price / Book | 5.1 |
| Price / CF | -148.7 |
| Current Ratio | 6.2 |
| Cur.Liabilities / Tot.Liabilities | 0.6 |
| Financial Leverage | 0.08 |
| in Mils USD |
rolling-year up to September
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Revenue |
233
|
256
|
224
|
205
|
184
|
184
|
|
| Gross Profit |
184
|
206
|
183
|
166
|
148
|
145
|
|
| R&D |
42
|
37
|
28
|
24
|
24
|
31
|
|
| EBITDA |
-17
|
2
|
6
|
3
|
-41
|
-35
|
|
| Operating Income |
-22
|
-4
|
1
|
-1
|
-45
|
-38
|
|
| Net Income exc. Extra |
-
|
-
|
1
|
-
|
-
|
-
|
|
| per Share | |||||||
| Diluted avg Shares |
39
|
34
|
33
|
33
|
33
|
32
|
|
| EPS exc. Extra |
-0.67
|
-0.10
|
0.02
|
-0.06
|
-1.37
|
-1.19
|
|
| Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
| Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Total Assets |
342
|
217
|
200
|
190
|
138
|
162
|
|
| Cash, Eq & Invt ShortTerm |
223
|
105
|
114
|
105
|
59
|
78
|
|
| Total Current Assets |
285
|
162
|
165
|
156
|
102
|
123
|
|
| Total Non-Current Assets |
56
|
55
|
36
|
35
|
36
|
39
|
|
| Intangibles |
16
|
21
|
6
|
5
|
4
|
5
|
|
| Total Liabilities |
73
|
75
|
66
|
70
|
35
|
32
|
|
| Total Current Liabilities |
46
|
47
|
36
|
36
|
30
|
30
|
|
| Long Term Debt |
28
|
28
|
30
|
34
|
5
|
2
|
|
| Shareholder equity |
268
|
142
|
134
|
120
|
103
|
131
|
|
| Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Cash from Operations |
-9
|
6
|
11
|
19
|
-21
|
-23
|
|
| Depreciation |
4
|
4
|
4
|
4
|
4
|
3
|
|
| Cash from Investing |
-92
|
-58
|
-5
|
-2
|
-2
|
-20
|
|
| Capex |
4
|
3
|
2
|
1
|
2
|
19
|
|
| Cash from Financing |
135
|
-2
|
2
|
30
|
4
|
3
|
|
| Stock Issued |
139
|
4
|
4
|
9
|
4
|
4
|
|
| Debt (LT) Issued |
0
|
0
|
0
|
21
|
0
|
-1
|
|
| Free Cash Flow |
-24
|
-2
|
-3
|
0
|
-41
|
-69
|
|
| Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
| Net Profit Margin |
-
|
-
|
0.4%
|
-
|
-
|
-
|
|
| NCFO / Op.Income |
-
|
-
|
1,070.7%
|
-
|
-
|
-
|
|
| Current Ratio |
6.2
|
3.5
|
4.5
|
4.3
|
3.4
|
4.1
|
|
| Financial Leverage D/E |
0.08
|
0.15
|
0.16
|
0.18
|
0.00
|
0.00
|
|
| Return on Capital Avg |
-14.7%
|
-1.2%
|
5.7%
|
-1.8%
|
-84.6%
|
-84.4%
|
|
| Return on Shareholder Equity |
-
|
-
|
0.6%
|
-
|
-
|
-
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available